Search clinical trials for: SYMTUZA DOLUTEGRAVIR

Total 229 results

Pedro Cahn
ViiV Healthcare

Withdrawn

Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study (PADDLE184V)

HIV-1 Infection

Argentina
University College Dublin
ViiV Healthcare; Mater Misericordiae University Hospital

Terminated

Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs (TAISTR)

Human Immunodeficiency Virus

Ireland
University Hospital Virgen de las Nieves

Unknown

Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients (DOLAVI)

HIV-1-infection

Spain
PENTA Foundation
Baylor College of Medicine; University Hospital Birmingham NHS Foundation Trust and other collaborators

Recruiting

DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old (D3 (Penta21))

HIV Infections

Spain, United Kingdom, Thailand, South Africa, Uganda
Instituto de Investigación Sanitaria de la Fundación...

Completed

REal-Life Cohort With DOlutegravir + LAmivudina (REDOLA)

HIV-1-infection

Spain
Fundação Bahiana de Infectologia
GlaxoSmithKline

Completed

DTG Plus 3TC for Prophylaxis of Mother-to-child Transmission of HIV Infection in Pregnant Women (PREGNANCY)

HIV Infections | Pregnancy Related | Mother to Child Transmission

Brazil
Instituto de Investigación Hospital Universitario...

Unknown

Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.

HIV-1-infection

Spain
Nantes University Hospital

Completed

Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD) (SWAD)

HIV-1 Infection

France
PENTA Foundation
Radboud University Medical Center; Baylor College of Medicine; Clinton Health... and other collaborators

Not yet recruiting

UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children (UNIVERSAL1)

HIV Infection
Macquarie University, Australia
King's College London; Stichting TRICALS Foundation

Recruiting

Triumeq in Amyotrophic Lateral Sclerosis (LIGHTHOUSE II)

Amyotrophic Lateral Sclerosis

Spain, Australia, United Kingdom, New Zealand, Netherlands, Ireland, Slovenia, Sweden
Fundacion SEIMC-GESIDA
ViiV Healthcare

Completed

Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine (VOLVER)

HIV Infections

Spain
ViiV Healthcare

Completed

'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

HIV Infections

Spain
St Stephens Aids Trust
ViiV Healthcare

Completed

SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over

HIV

United Kingdom
St Stephens Aids Trust
ViiV Healthcare

Completed

SSAT061: PK of DTG and EVT/COBI in Healthy Volunteers

HIV

United Kingdom
Southern Illinois Healthcare Foundation
Janssen Scientific Affairs, LLC

Completed

A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir

HIV-1-infection
IRCCS San Raffaele
Gilead Sciences

Terminated

Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE) (Be-OnE)

HIV-1-infection

Italy
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States
Insel Gruppe AG, University Hospital Bern
University of Bern; Center for Primary Care and Public Health (Unisante), University...

Enrolling by invitation

B-free Multistage Trial (B-free)

HIV | Drug Resistance | Drug Drug Interaction

Switzerland
Neuroscience Trials Australia
Macquarie University, Australia; Calvary Health Care Bethlehem; Westmead Hosptial and other collaborators

Completed

Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS). (Lighthouse)

Amyotrophic Lateral Sclerosis

Australia
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Evaluation of the Bioequivalence of a Combined Formulated Tablet

Infection, Human Immunodeficiency Virus

United States
Azienda Ospedaliera Città della Salute e della...

Completed

Effect of Inhalatory Sedation in Subarachnoid Hemorrhage (INSPIRE)

Subarachnoid Hemorrhage | Aneurysmal Subarachnoid Hemorrhage

Italy
Emory University
National Institute of Allergy and Infectious Diseases (NIAID)

Terminated

Dolutegravir in Reservoirs

HIV

United States
Babafemi Taiwo
ViiV Healthcare

Completed

Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE)

HIV Infection

United States
ANRS, Emerging Infectious Diseases
MSD France

Not yet recruiting

DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection (ELDORADO)

HIV-1-infection

Brazil, Cambodia, Cameroon, Côte D'Ivoire, France, Mozambique
Duke University
The Emmes Company, LLC

Recruiting

Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in Botswana (BMS02)

HIV Infections | Lactating Women on Select DOI | Breastmilk Fed Infants of Mothers on Select DOI

South Africa
University of Maryland, Baltimore

Completed

Switch to Maraviroc + Integrase Inhibitor

HIV

United States
ViiV Healthcare
MUC Research GmbH

Completed

Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1 (JUNGLE)

HIV Infections

Germany
Fundacion IDEAA
ViiV Healthcare

Completed

Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test (D2ARLING)

Hiv | HIV-1-infection

Argentina
Charlotte-Paige Rolle, MD
ViiV Healthcare

Completed

Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF (DYAD)

HIV I Infection

United States
Fundacion SEIMC-GESIDA
ViiV Healthcare

Active, not recruiting

DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV: (PASO-DOBLE)

HIV-1-infection

Spain
NEAT ID Foundation
ViiV Healthcare

Completed

An Open-Label, Multi-Centre, Randomised, Switch Study to Evaluate the Virological Efficacy Over 96 Weeks Of 2-Drug Therapy With DTG/RPV FDC in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTIs Resistance Mutation K103N (WISARD)

HIV-1-infection

Spain, Belgium, France, Germany, Italy, United Kingdom
Philip Grant

Withdrawn

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew) (ReNew)

HIV/AIDS | Osteopenia | HIV-1-infection

United States
MRC/UVRI and LSHTM Uganda Research Unit
Janssen Pharmaceuticals

Recruiting

Improving HIV-1 Control in Africa With Long Acting Antiretrovirals (IMPALA)

HIV-1-infection

South Africa, Kenya, Uganda
Andrew Carr
ViiV Healthcare Australia Pty. Ltd

Completed

The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis (dPEP)

Human Immunodeficiency Virus

Australia
Indiana University

Completed

Pharmacokinetics of JULUCA in Hemodialysis

HIV/AIDS | ESRD

United States
ViiV Healthcare

Completed

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

HIV Infections

United States
ViiV Healthcare
GlaxoSmithKline

Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, Argentina, Spain, Germany, Belgium, Australia, Canada, United Kingdom, Italy, Romania, Taiwan, Russian Federation, Mexico, France, Switzerland, Peru, Poland, Portugal
Fondation Ophtalmologique Adolphe de Rothschild

Terminated

Evaluation of Neurologic and Psychiatric Adverse Events of Several Antiretroviral Drugs in Real Life Setting (NEPAL)

HIV

France
ANRS, Emerging Infectious Diseases

Recruiting

Evaluation of Third-line cART Regimen in Cambodia (3DICAM)

HIV/AIDS

Cambodia
ViiV Healthcare
GlaxoSmithKline; PPD

Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

HIV Infections | Infection, Human Immunodeficiency Virus

Taiwan, France, Germany, Belgium, United States, Canada, Netherlands, Spain, Korea, Republic of, Italy, Australia, United Kingdom, Russian Federation, Portugal, Argentina, South Africa, Romania, Mexico
University of North Carolina, Chapel Hill
ViiV Healthcare

Completed

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection (PHI-05)

HIV | Acute HIV Infection

United States
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Completed

Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density

HIV-1 Infection

Spain
Azienda Ospedaliera Universitaria Senese
Catholic University of the Sacred Heart; Ospedale Policlinico San Martino; Azienda... and other collaborators

Unknown

Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen (DOBINeuro)

HIV-1-infection

Italy
ViiV Healthcare
GlaxoSmithKline

Completed

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects (FLAMINGO)

Infection, Human Immunodeficiency Virus

Spain, France, Germany, United States, Italy, Romania, Russian Federation, Switzerland, Puerto Rico
Johns Hopkins University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Rapid HIV Treatment Initiation, Access and Engagement in Care

Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Infection, Human Immunodeficiency Virus I

United States, Spain, Germany, Australia, Canada, Belgium, Denmark, Netherlands, United Kingdom, France, Italy, Romania
Centre for the AIDS Programme of Research in South...
Johns Hopkins University; National Institute of Allergy and Infectious Diseases... and other collaborators

Active, not recruiting

INSTI's For The Management of HIV-associated TB (INSIGHT)

HIV/AIDS | Tuberculosis, Pulmonary

South Africa
Cristina Mussini

Unknown

Evaluating Inflammatory and Immunological Changes of HIV-positive Patients Switching to DTG Dual Regimen Compared to Those Switching to a Triple Drugs Regimen (B/F/TAF)

HIV Infections
ANRS, Emerging Infectious Diseases
Mylan Laboratories

Active, not recruiting

ANRS 12372 MODERATO Study (MODERATO)

HIV-1-infection

Côte D'Ivoire, Burkina Faso, Cameroon
Desmond Tutu TB Centre
University of Stellenbosch; UNITAID; Chiang Mai University

Recruiting

Pharmacokinetics and Safety of DolutegravIr in Neonate (PETITE-DTG)

Hiv

South Africa

Search clinical trials for: SYMTUZA DOLUTEGRAVIR

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations